DUBLIN, Ireland, July 20, 2021 /PRNewswire/ -- Theravance
Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical
company primarily focused on the discovery, development and
commercialization of organ-selective medicines, will report its
second quarter 2021 financial results and provide a business update
after market close on Tuesday, August 3,
2021. An accompanying conference call and simultaneous
webcast will be hosted at 5:00 p.m.
ET (2:00 p.m. PT/10:00 p.m. IST) that day.
Conference Call Information
To participate in the live call by telephone, please dial (855)
296-9648 from the US or (920) 663-6266 for international callers,
using the confirmation code 2615108. Those interested in listening
to the conference call live via the internet may do so by visiting
Theravance Biopharma's website at www.theravance.com, under the
Investors section, Presentations and Events.
A replay of the conference call will be available on Theravance
Biopharma's website for 30 days through September 2, 2021. An audio replay will also be
available through 8:00 p.m. ET on
August 10, 2021 by dialing (855)
859-2056 from the US, or (404) 537-3406 for international callers,
and then entering confirmation code 2615108.
About Theravance Biopharma
Theravance Biopharma, Inc. is a diversified biopharmaceutical
company primarily focused on the discovery, development and
commercialization of organ-selective medicines. Its purpose is to
pioneer a new generation of small molecule drugs designed to better
meet patient needs. Its research is focused in the areas of
inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights
and innovation at each stage of its business and utilizes its
internal capabilities and those of partners around the world. The
Company applies organ-selective expertise to target disease
biologically, to discover and develop medicines that may expand the
therapeutic index with the goal of maximizing efficacy and limiting
systemic side effects. These efforts leverage years of experience
in developing lung-selective medicines to treat respiratory
disease, including FDA-approved YUPELRI® (revefenacin)
inhalation solution indicated for the maintenance treatment of
patients with chronic obstructive pulmonary disease (COPD). Its
pipeline of internally discovered programs is targeted to address
significant patient needs.
Theravance Biopharma has an economic interest in potential
future payments from Glaxo Group Limited or one of its affiliates
(GSK) pursuant to its agreements with Innoviva, Inc. relating to
certain programs, including TRELEGY.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and
the Cross/Star logo are registered trademarks of the Theravance
Biopharma group of companies (in the U.S. and certain other
countries).
YUPELRI® is a registered trademark of Mylan Specialty
L.P., a Viatris Company. Trademarks, trade names or service marks
of other companies appearing on this press release are the property
of their respective owners.
Contact Information:
Gail Cohen
Corporate Communications
917-214-6603
investor.relations@theravance.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-second-quarter-2021-financial-results-on-august-3-2021-301336853.html
SOURCE Theravance Biopharma, Inc.